Targeted Therapy to Increase RAI Uptake in Metastatic DTC

Part of paid clinical trials in San Francisco, California.

Sponsor
Children's Hospital of Philadelphia
Study ID
NCT05024929
Status
Recruiting
Apply to this trial

Conditions

  • Differentiated Thyroid Cancer
  • Papillary Thyroid Cancer
  • Pediatric Cancer

Eligibility Criteria

Sex
ALL
Age
0 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Whole body scan — PROCEDURE
    Patients will receive oncogene-specific molecularly targeted therapy independently of this protocol either via commercial supply of an FDA approved agent, or as part of a separate therapeutic clinical trial/compassionate use protocol/single patient investigational new drug (IND). During screening, patients will undergo a baseline RAI-whole body scan (WBS) to assess RAI-avidity of their tumor per standard of care. Following approximately 28 days of targeted therapy, the WBS will be repeated to determine whether this therapy is associated with an increase in RAI-avidity of their tumor.

Study Details

Papillary thyroid cancer (PTC) is a common type of differentiated thyroid cancer (DTC) in children and represents the second most common cancer in adolescent females. Recently targeted drugs that block many of the genetic drivers of DTC have become available. While Investigators know that these drugs shrink DTC tumors in many cases, the impact on radioactive iodine (RAI) avidity has not been systematically studied.

Key Dates

Start date
Jul 16, 2021
Status verified
Nov 2025
Primary completion
Feb 1, 2031
Completion
Feb 1, 2033

Study Design

Enrollment
32 participants (estimated)

Arms

  • Arm: Prospective Cohort
    Patients with differentiated thyroid cancer for whom oncogene-specific targeted therapy is planned from commercial supply or as part of a separate therapeutic trial
  • Arm: Data Sharing Cohort
    Patients with differentiated thyroid cancer enrolled on other oncogene-specific targeted therapy trials who undergo whole body thyroid scan approximately 28 days after beginning targeted therapy and agree to data sharing

Primary Outcome Measure

Proportion of patients with increased tumor RAI-avidity after receiving oncogene-specific, targeted therapy [ Time Frame: up to 5 years ]

Central Contacts

Locations (8)

FacilityCityStateZIPSite coordinators
University of California San FranciscoSan FranciscoCalifornia94143
Arun Rangaswami, MD
[email protected]
415-298-9434
Karina Wong
[email protected]
415-298-9434
Emory University School of MedicineAtlantaGeorgia30322
Brianna Patterson, MD
Boston Children's HospitalBostonMassachusetts02115
Junne Kamihara, MD
Junne Kamihara, MD (PRINCIPAL_INVESTIGATOR)
Children's Hospital of PhiladelphiaPhiladelphiaPennsylvania19104
Meghan T Donnelly
[email protected]
267-436-9343
James Robinson
[email protected]
215-590-2053
Theodore Laetsch, MD (PRINCIPAL_INVESTIGATOR)
St. Jude Children's Research HospitalMemphisTennessee38105
Sara Helmig, MD
MD Anderson Cancer CenterHoustonTexas77030
Steven Waguespack, MD
Steven Waguespack, MD (PRINCIPAL_INVESTIGATOR)
Texas Children's HospitalHoustonTexas77030
Rajkumar Venkatramani, MD
Priya Mahajan, MD (PRINCIPAL_INVESTIGATOR)
Seattle Children's HospitalSeattleWashington98105
Tyler Ketterl, MD, MS
Tyler Ketterl, MD, MS (PRINCIPAL_INVESTIGATOR)

Find similar trials in San Francisco, CA

By research site
University of California San Francisco· San Francisco, CAEmory University School of Medicine· Atlanta, GABoston Children's Hospital· Boston, MAChildren's Hospital of Philadelphia· Philadelphia, PASt. Jude Children's Research Hospital· Memphis, TNMD Anderson Cancer Center· Houston, TX

Related Studies